Adaptive Biotechnologies Stock: 5 Straight Green Days, Up 18%
A recent run has put the stock in the spotlight, but the underlying numbers tell a more complicated story.
A five-day run in Adaptive Biotechnologies (ADPT) stock has added about $705 million to its market value. The stock has now moved higher for 5 consecutive trading days, a cumulative gain of 18.2% that brings its total market capitalization to about $4.6 billion.
For anyone holding the stock, this recent performance stands out. Adaptive Biotechnologies stock trades at about $28.61 a share as of 9/18/2026.
ADPT versus the S&P 500, streak and beyond
Here is how ADPT stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | ADPT | S&P 500 |
|---|---|---|
| 1D | 0.2% | 0.2% |
| 5D (Current Streak) | 18.2% | -0.1% |
| 1M (21D) | 12.2% | -0.7% |
| 3M (63D) | 63.2% | 2.0% |
| YTD 2026 | 76.2% | 11.8% |
| 2025 | 170.9% | 16.4% |
| 2024 | 22.3% | 23.3% |
| 2023 | -35.9% | 24.2% |
What does the data show about this run?
The run followed twin catalysts: updated NCCN guidelines explicitly incorporating clonoSEQ for myeloma testing, and management’s strategy update at the Morgan Stanley Healthcare Conference regarding plans to separate its MRD diagnostics and drug-discovery operations.
While the gain appears to be the stock’s own story, as over the same 5 trading days the S&P 500 returned -0.1%, the company’s fundamentals present a mixed picture when measured against large-cap industry peers in the S&P 500 Health Care sector.
Revenue over the last twelve months grew 50.1%, well above the median of 8.1%. However, its operating margin over the last twelve months is -12.2%, compared to a median of 17.6%. ADPT also has negative trailing earnings, so it does not have a meaningful price-to-earnings multiple.
A streak is information, not an instruction.
A streak of this kind is a signal about momentum and investor attention. It is not, by itself, a reason to buy or sell. The disciplined response is to treat the new price as an occasion to re-evaluate the business.
The price of a stock is a vote on its future, while the fundamentals are a report on its past. The numbers here provide a starting point to weigh one against the other.
A climb like this is worth respecting, and worth testing: the momentum that lasts is usually the kind management itself is underwriting. Our Guidance Momentum screen tracks the stocks whose companies just raised their own forward numbers.
And for anyone who would rather back the theme than one company’s story, our ETF Scorecard shows how the health care funds stack up. Any one of those funds is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
One hot stock is a story. Thirty sound ones are a strategy
A streak like this earns a place on your watchlist, and it also earns a question: how much of your outcome do you want depending on one company keeping this up?
The Trefis High Quality (HQ) Portfolio answers it with breadth: roughly 30 businesses picked for consistent cash generation, strong margins, and balance-sheet strength, sized and rebalanced by rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Follow the story; invest in the strategy.